- Home
- BIIB vs CHKP Comparison
BIIB vs CHKP Comparison
Compare BIIB & CHKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CHKP
- Stock Information
- Founded
- BIIB 1978
- CHKP 1993
- Country
- BIIB United States
- CHKP Israel
- Employees
- BIIB 7605
- CHKP N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CHKP Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- CHKP Technology
- Exchange
- BIIB Nasdaq
- CHKP Nasdaq
- Market Cap
- BIIB 20.6B
- CHKP 23.5B
- IPO Year
- BIIB 1991
- CHKP 1996
- Fundamental
- Price
- BIIB $140.60
- CHKP $216.80
- Analyst Decision
- BIIB Buy
- CHKP Hold
- Analyst Count
- BIIB 27
- CHKP 24
- Target Price
- BIIB $220.50
- CHKP $215.59
- AVG Volume (30 Days)
- BIIB 1.5M
- CHKP 1.0M
- Earning Date
- BIIB 02-12-2025
- CHKP 01-30-2025
- Dividend Yield
- BIIB N/A
- CHKP N/A
- EPS Growth
- BIIB 40.28
- CHKP 5.07
- EPS
- BIIB 11.18
- CHKP 7.46
- Revenue
- BIIB $9,675,900,000.00
- CHKP $2,565,000,000.00
- Revenue This Year
- BIIB N/A
- CHKP $8.11
- Revenue Next Year
- BIIB $1.57
- CHKP $5.52
- P/E Ratio
- BIIB $12.65
- CHKP $29.36
- Revenue Growth
- BIIB N/A
- CHKP 6.22
- 52 Week Low
- BIIB $128.51
- CHKP $145.75
- 52 Week High
- BIIB $238.00
- CHKP $226.03
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- CHKP 60.07
- Support Level
- BIIB $135.02
- CHKP $215.84
- Resistance Level
- BIIB $141.69
- CHKP $223.08
- Average True Range (ATR)
- BIIB 4.00
- CHKP 4.51
- MACD
- BIIB 0.04
- CHKP -0.46
- Stochastic Oscillator
- BIIB 59.44
- CHKP 53.24
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.